Physical Therapy for a Multiple Myeloma Patient with COVID-19: A Case Report-Reference-Cited by-同舟云学术

Physical Therapy for a Multiple Myeloma Patient with COVID-19: A Case Report

Published:2023 Issue:0 Volume:8 Page:n/a
ISSN:2432-1354
Container-title:Progress in Rehabilitation Medicine
language:en
Short-container-title:PRM

Author:

Osaki Keiichi¹,Morishita Shinichiro²,Shimokawa Tetsuhiro¹,Kamimura Akiho¹,Sekiyama Takashi¹,Kanehiro Chisaki¹,Shindo Atsushi¹,Shiga Kensuke³,Kawata Eri⁴

Affiliation:

1. Department of Rehabilitation, Panasonic Health Insurance Organization, Matsushita Memorial Hospital, Osaka, Japan

2. Department of Physical Therapy, School of Health Sciences, Fukushima Medical University, Fukushima, Japan

3. Department of General Medicine, Panasonic Health Insurance Organization, Matsushita Memorial Hospital, Osaka, Japan

4. Department of Hematology, Panasonic Health Insurance Organization, Matsushita Memorial Hospital, Osaka, Japan

Publisher

Japanese Association of Rehabilitation Medicine

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/prm/8/0/8_20230007/_pdf

Reference20 articles.

1. 1. Wang Q, Berger NA, Xu R: Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection. JAMA Oncol 2021;7:220–227. PMID:33300956, DOI:10.1001/jamaoncol.2020.6178

2. 2. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, Xiong Y, Xiong H, Wang C, Chen C, Xiong F, Zhang Y, Peng Y, Ge S, Zhen B, Yu T, Wang L, Wang H, Liu Y, Chen Y, Mei J, Gao X, Li Z, Gan L, He C, Li Z, Shi Y, Qi Y, Yang J, Tenen DG, Chai L, Mucci LA, Santillana M, Cai H: Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 2020;10:783–791. PMID:32345594, DOI:10.1158/2159-8290.CD-20-0422

3. 3. Sharafeldin N, Bates B, Song Q, Madhira V, Yan Y, Dong S, Lee E, Kuhrt N, Shao YR, Liu F, Bergquist T, Guinney J, Su J, Topaloglu U: Outcomes of COVID-19 in patients with cancer: Report from the National COVID Cohort Collaborative (N3C). J Clin Oncol 2021;39:2232–2246. PMID:34085538, DOI:10.1200/JCO.21.01074

4. 4. Herzog Tzarfati K, Gutwein O, Apel A, Rahimi-Levene N, Sadovnik M, Harel L, Benveniste-Levkovitz P, Bar Chaim A, Koren-Michowitz M: BNT162B2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies. Am J Hematol 2021;96:1195–1203. PMID:34185336, DOI:10.1002/ajh.26284

5. 5. Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, Fotiou D, Papanagnou ED, Migkou M, Theodorakakou F, Roussou M, Eleutherakis-Papaiakovou E, Kanellias N, Trougakos IP, Kastritis E, Dimopoulos MA: The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J 2021;11:138. PMID:34341335, DOI:10.1038/s41408-021-00530-3